

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 May 2025 (22.05.2025)



(10) International Publication Number
WO 2025/106549 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/44 (2006.01)
A61K 31/18 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/055737

(22) International Filing Date:

13 November 2024 (13.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/598,722 14 November 2023 (14.11.2023) US

(71) Applicant: **MAPLIGHT THERAPEUTICS, INC.**
[US/US]; 800 Chesapeake Drive, Redwood City, California
94063 (US).

(72) Inventors; and

(71) Applicants: **KENT, Caitlin** [US/US]; c/o MapLight Therapeutics, Inc., 800 Chesapeake Drive, Redwood City, California 94063 (US). **SYLVESTER, Mark** [US/US]; c/o MapLight Therapeutics, Inc., 800 Chesapeake Drive, Redwood City, California 94063 (US). **WOOD, Michael** [US/US]; c/o MapLight Therapeutics, Inc., 800 Chesapeake Drive, Redwood City, California 94063 (US).

(74) Agent: **YOUN, Dou Yeon** et al.; Cooley LLP, 1299 Pennsylvania Ave., NW., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: GPR52 MODULATORS



(57) Abstract: Provided herein are compounds of Formula (I) or pharmaceutically acceptable salts, stereoisomers thereof, and compositions thereof, wherein Cy¹, Cy², Cy³, Cy⁴, R¹, R², L, and Z are defined herein. The disclosed compounds are useful for treating various diseases and disorders.

WO 2025/106549 A1